University of Pittsburgh receives $100 million to enhance trauma care research

He­paran sul­fate, a po­ten­tial new sur­ro­gate bio­mark­er for neu­rode­gen­er­a­tive dis­eases, is get­ting a lot of love from biotechs this week. De­nali Ther­a­peu­tics on Wednes­day pre­sent­ed

Any­one lis­ten­ing to Sarep­ta’s call Mon­day af­ter the biotech re­leased tri­al da­ta for its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py would have thought the com­pa­ny hit